Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Non-Hodgkin Lymphoma · Advanced Solid Tumors · ADCT

ADC Therapeutics

ADC Therapeutics SA

ADC Therapeutics patent portfolio — 22 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Lausanne, Vaud, Switzerland, CH HQ
2011 Founded
272 Employees
Public company Type
ADCT · NYSE Ticker
Company details
Status
Public
HQ
Lausanne, Vaud, Switzerland, CH
Founded
2011
Employees
272
Programs
30
Drugs
15
Patents
22
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

ADC Therapeutics patents

22 pharmaceutical patents indexed for ADC Therapeutics. 0 expire within 24 months.

ADC Therapeutics has 22 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

22 patents

Patent portfolio

  1. US 11976122

    Anti-IL13Rα2 antibodies

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11938192

    Dosage regimes for the administration of an anti-CD19 ADC

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11813335

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11702473

    Site-specific antibody-drug conjugates

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11690918

    Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11596696

    Combination therapy with an anti-CD25 antibody-drug conjugate

    Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11426467

    Dosage regimes for the administration of an anti-CD25 ADC

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11384098

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11318211

    Dosage regimes for the administration of an anti-CD19 ADC

    Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11160872

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11084872

    Method for treating breast cancer

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10799596

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10780096

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10722594

    Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10597450

    Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10544223

    Combination therapy with an anti-axl antibody-drug conjugate

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10017580

    Humanized anti-Tn-MUC1 antibodies and their conjugates

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9931415

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9931414

    Pyrrolobenzodiazepine-antibody conjugates

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9919056

    Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9855291

    Anti-kidney associated antigen 1 (KAAG1) antibodies

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9828426

    Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does ADC Therapeutics have?

22 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do ADC Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.